Cargando…
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Almost 50% of metastatic melanoma patients harbor a BRAF(V600) mutation andthe introduction of BRAF inhibitors has improved their treatment options. BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutate...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279367/ https://www.ncbi.nlm.nih.gov/pubmed/25344914 |